Tango Therapeutics, Inc. (TNGX) Stock Research
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Latest price: 24.3 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Newcomb Jessica | sell | 2026-09-22 | 122238.33 |
| Newcomb Jessica | sell | 2026-09-22 | 15962.03 |
| Newcomb Jessica | sell | 2026-09-22 | 60412.32 |
| Crystal Adam | sell | 2026-09-01 | 603909 |
| Crystal Adam | sell | 2026-08-03 | 594417.11 |
| Crystal Adam | sell | 2026-08-03 | 141100.3 |
| Crystal Adam | sell | 2026-07-01 | 575961.97 |
| Crystal Adam | sell | 2026-07-01 | 222946.21 |
| Crystal Adam | sell | 2026-05-01 | 24196.04 |
| Crystal Adam | sell | 2026-05-01 | 548901.29 |